BALB/c radiation leukemia RLCel is an immunogenic tumor. We established bulk and cloned cytotoxic T lymphocyte (CTL) lines from regressor (BALB/c x C57BL/6)F1 (CB6F 0 spleen cells that recognized ILLo'I specifically. We then obtained antigen peptide recognized by CTL from ILLcYl by acid extraction. Analysis of the acid extract by reversed-phase high performance liquid chromatography (HPLC) on a semipreparative C18 column revealed that fractions eluted in 23 min (peak a) and 26 min (peak b) showed sensitization activity on the P815 target for specific CTL. On further purification of these fractions by HPLC and direct sequencing by Edman degradation, we identified the CTL-recognizing RLO'I peptide piLLla (IPGLPLSL) in peak a and its possible precursor peptide pRLlb (SIIPGLPLSL) in peak b. Sequence homology indicated that these peptides were derived from the 5' untranslated region of c-akt oncogene.
T
umor rejection antigens were first found on methylcholanthrene-induced fibrosarcomas in mice (1) (2) (3) (4) (5) . Immunization of syngeneic mice with a tumor was shown to render these mice resistant to successive challenge by the same tumor. A characteristic of tumor rejection antigens is extremely high polymorphism. In fact, even two tumors in the same animal possess different rejection antigens (6) . These individually distinct antigens were later found on a variety of tumors of many other histological types in different species.
Studies on adoptive transfer showed that the tumor rejection response is mediated by T cells (7, 8) ; CD8 + T cells are predominantly responsible for rejection, whereas CD4 + T cells are involved to various extents depending on the tumor. It is generally accepted that the effector cells are mainly CD8 + CTL and that CD4 + T cells help CD8 + CTL precursors to differentiate into effector cells (9, 10) . In cases not involving CD4 + T cells, CD8 + helper cells participate in CTL induction (10) .
BALB/c radiation-induced leukemia RLo'I is a highly immunogenic tumor. In BALB/c mice hybridized with certain mouse strains, inocula of ILLO'I cells initially grew, formed a tumor, and then regressed. The different immune responsivenesses to RLcYl rejection antigen of the various mouse strains used for producing F1 hybrids have been ascribed to a gene located in the H-2K region (11) . Spleen cells from regressor (BALB/c x C57BL/6)F1 (CB6F1) 1 mice generate CD8 + CTL after in vitro stimulation (12) . CTL have been shown to recognize RLCYl, but not other ILL series of leukemias, radiation-leukemia virus-induced leukemias, fibrosarcomas, or blasts from normal lymphoid cells. These findings suggest that there is a unique (individually distinct) antigen on RLcYl. Adoptive transfer of CTL to BALB/c nu/nu mice protected the recipient mice from subsequent challenge with RLo'I cells (13) . In vivo depletion of CD8 + T cells abrogated the rejection, whereas depletion of CD4 + T cells had little effect (14, 15) . These findings suggest that the RLo'I rejection response is mediated by CD8 + CTL. In this study, we identified a unique rejection antigen peptide, pILL1, that is recognized on RLCYl by CTL derived from semisyngeneic CB6F1 mice. Sequence homology analysis revealed that pILL1 is derived from the 5' untranslated region of c-akt oncogene (16) .
Materials and Methods
Mice. BALB/c, C57BL/6 (B6), and CB6F1 mice were purchased from Japan SLC Co. (Shizuoka, Japan). Breeding pairs of BALB.B mice were provided by Dr. H. Fujiwara (Osaka University Medical School, Osaka, Japan). These mice were bred in our animal center.
Tumors and Cell Lines. RLCel, RLCY4, and RL98 are radiationinduced leukemias in BALB/c mice (12) . RVA, RVC, and RVD are leukemias induced by injection of radiation leukemia virus into neonatal BALB/c mice (17) . P815 is a methylcholanthrene-induced mastocytoma in a DBA/2 mouse (18). These tumors were maintained in the strain of origin. T1.1.1 and T4.8.3 are derivatives of L cells (H-2 ~) transfected with the H-2L a and H-2D d gene, respectively (19) , and were provided by Dr. N. Shinohara (Mitsubishi Kasei Institute of Life Science, Machida, Japan).
Antibodies. Anti-L3T4 (CD4) mAb, a rat antibody of the IgG2b immunoglobulin class, produced by hybridoma GK1.5 (20) , was provided by Dr. F. Fitch (University of Chicago, Chicago, IL). AntiLyt-2.2 (CDS) mAb, a mouse antibody of the IgG2a class, produced by hybridoma 19/178 was provided by Dr. U. H~immerling (Memorial Sloan-Kettering Cancer Center, New York). Anti-TCR-j8 mAb, a hamster antibody of the IgG class, produced by hybridoma H57-597 (21) was provided by Dr. R. Kubo (National Jewish Center, Denver, CO). Anti-CD3e mAb, a hamster antibody of the IgG class, produced by hybridoma 145-2Cll (22) , was provided by Dr. J. A. Bluestone (University of Chicago). Anti-H-2K d and anti-H-2D d mAbs are mouse antibodies of the IgG2a class produced by hybridomas KD40 and DD98, respectively, that were established by hybridization of P3U1 myeloma and spleen cells from BALB.B mice that had been immunized with BALB/c lymphoid cells. Anti-H-2L a mAb is a mouse IgG2a antibody produced by a hybridoma 30-5-7 (23) . Anti-lA d mAb is a mouse IgG2b antibody produced by hybridoma MK-D6 (24) . Anti-IE k,a mAb is a mouse IgG2b antibody produced by hybridoma ISCR3 (25) . These mAbs were provided by Dr. N. Shinohara.
Peptide Synthesis and Purification. Peptides were synthesized by standard solid-phase methods using Fmoc chemistry in a Peptide synthesizer (model 430A; Applied Biosystems, Foster City, CA). Cleavage of the peptide from the resin and removal of the side chain protecting groups were carried out using 95% trifluoroacetic acid (TFA). The peptides were purified to >98% homogeneity by reversed-phase HPLC on a preparative C8 column (10 x 100 mm, 20/ira particle size; Applied Biosystems) in 0.1% TFA with an acetonitrile gradient. The purity ofpeptides was assayed in an analytical C18 column (4.6 x 150 mm, 5 #m particle size; Chemco, Osaka, Japan). The integrity of the purified Peptides was confirmed by fast atom bombardment mass spectrometry (model 9020-DF; Shimazu, Kyoto, Japan).
Sequence Analysis. Sequencing was Performed by NH2-terminal
Edman degradation using a protein sequencer (model 477A; Applied Biosystems, Inc.) coupled to a phenyl thiohydantoin analyzer (model 120A; Applied Biosystems, Inc.). Amino acid sequence homology was investigated using the National Biomedical Research Foundation (NBRF) database using GENETYX-MAC (Genetic Bio Database Software, Software Development Co., Tokyo, Japan).
Acid Extraction of Whole Cells and HPLC Analysis. Samples of 2.5 x 1011 RLcYl ascites cells from 250 BALB/c mice were homogenized by 10 strokes in 0.1% TFA with a Dounce homogenizer and sonicated (Sonifier W-185; Branson Sonic Power, Danbury, CT) for 3 min. The homogenates were then stirred at pH 2.0 in 0.1% TFA for 30 rain. The supernatants obtained by centrifugation at 100,000 g for 30 min were filtered with a molecular cut-off membrane (m.w. 5000, PLCC; Millipore Corp., Bedford, MA). These procedures were clone at 4~ The filtrates obtained from 10 mice were lyophilized, resolved in 0.1% TFA, and analyzed by reversedphase HPLC (model 625L; Waters/Millipore, Milford, MA) on a semipreparative C18 column (ODP, 10 x 250 ram, 10/~m particles; Asahipak, Kawasaki, Japan). Solvent A was 0.1% TFA and solvent B was acetonitrile containing 0.1% TFA. The gradient for chromatography was 20-60% B over 40 min. The fractions (2.0 ml) collected at 1 min intervals were assayed for sensitization activity on P815 cells for anti-RLcYl CTL (see below). Reversedphase HPLC on a semipreparative C18 (ODP) column was repeated 25 times. Active fractions were pooled and subjected to reversedphase HPLC on an analytical C2/C18 column (SuperPac TM Pep-S, 4 x 250 mm, 5/zm particles; Pharmacia LKB, Uppsala, Sweden) at neutral pH. For peak a obtained in the first round of HPLC analysis on the C18 (ODP) column (see Fig. 2 in the Results section), solvent A was 25% acetonitrile, and solvent B was 40% acetonitrile, with a gradient of 0-100% B over 30 rain. For peak b obtained on the C18 (ODP) column, solvent A was water, and solvent B was 50% acetonitrile, with a gradient of 0-100% B over 30 min followed by isocratic elution with 100% B for 10 rain. Fractions (1.0 ml) collected at 1 rain intervals were assayed for sensitization activity as described above. Active fractions were pooled and that of peak a but not peak b was subjected to gel-filtration (ProteinPak TM 60 column, 7.8 • 300 mm, 10 #m particles; Waters Millipore) and then reversed-phase HPLC on a C2/C18 column under acidic conditions. For peak a, solvent A and B were 25 and 40% acetonitrile, respectively, containing 0.1% TFA. The gradient was 0-100% B over 60 min. For peak b, solvent A was 0.1% TFA, and solvent B was 50% acetonitrile, containing 0.1% TFA. The gradient was 0-100% B for 30 min followed by isocratic elution with 100% B over 10 min. Fractions (250 and 100/~1) were collected at intervals of 0.25 and 0.1 min, respectively, and tested for sensitizing activity.
Acid Elution from Affinity-purified H-2L ~. Cells were lysed in a solution (lysis buffer) of 0.5% NP-40, 10 mM Tris-HC1 (pH 7.5), 0.2 mM p-amidinophenyl (pA)-PMSF, 5 mM EDTA, 5/lg/ml pepstatin A, and 5/~g/ml aprotinin. The supernatant obtained by centrifugation at 100,000 g for 30 min was diluted to 0.1% NP-40 and loaded onto anti-L d mAb (30-5-7)-coupled Afhgel-hydrazide (Bio-Rad Laboratories, Inc., Richmond, CA). The column was washed extensively with 60 vol of a solution of 10 mM Tris-HC1 (pH 7.5), 0.2 mM pA-PMSF, 5 mM EDTA, and 150 mM NaC1, and then bound material was eluted with 0.1% TFA. The eluate was filtered on a PLCC membrane with a cut off of m.w. 5,000 (PLCC 5,000). The filtrate was lyophilized and dissolved in 0.1% TFA for reversed-phase HPLC. Leukemia Antigen Peptide Recognized by CTL growing cells was tested. Six clones were chosen and maintained by weekly stimulation as described above.
Generation of Con

Cell-mediated Cytotoxicity Assay. Tumor cells and Con A blasts
were labeled by incubating 2 x 106 cells with 2 MBq of Na251CrO4 (New England Nuclear, Boston, MA) in 0.3 ml of medium for 1 h at 37~ under 5% CO2 in air. The cells were then washed and used as target cells. In direct assays, 104 labeled target cells (100 #1) were incubated with the effector cell suspension (100/A). In antibody blocking assays, serially diluted mAb (100/A) was added to the culture of effector cells (50 #1) and labeled target cells (50/A). In competitive inhibition assays, unlabeled inhibitor cells (50/A) with or without sensitization by the peptide-containing HPLC fraction were added at different ratios to 104 SlCr-labeled RLO'I target cells (100 /A), and then the effector cells (50/~1) were added. In sensitization assays, 5 -10/A of HPLC fractions or peptide solution in 100 #1 of medium were added to 104 SlCr-labeled target cells (50/A) and incubated for 60 min at room temperature before adding effector cells (50/A). After incubation for 4 h at 37aC under 5% CO2 in air, the supernatants (100/zl) were removed and their radioactivity was measured. The percentage of specific lysis was calculated by the following equation:
, where a is the radioactivity in the supernatant of target cells mixed with effector ceils, b is that in the supernatant of target cells incubated alone, and c is that in the supernatant after lysis of target cells with 1% NP-40. 
Results
Generation of Bulk and Cloned CTL Lines Specific for RLCYl. Inoculation of 106 RLcYl cells into the back of
CB6F1 mice results in formation of a tumor and then its regression (11) . When spleen ceils obtained from mice after tumor regression were cultured with irradiated (100 Gy) RLo'I ceils, cytotoxicity against the RLCrl cells was generated in 5 d (12) . The culture was maintained as a bulk CTL line by weekly repeated stimulation with 105 irradiated (100 Gy) RLO'I cells and 5 x 106 irradiated (20 Gy) CB6F1 splenic feeder cells in the presence of rlL-2 in 24-well culture plates. A culture from different mice was used for cloning. The cells were diluted to 3-0.3 cells/well and stimulated with 104 irradiated RLcyl ceils and 106 irradiated CB6F1 splenic feeder ceils in the presence of rlL-2 in 96-well culture plates. After culture for 10-14 d, the cytotoxicity of clonally growing cells was tested using half the culture. The other half was maintained as a clone by repeated stimulation as described above. We established six cloned CTL lines: clone 12, 14, 31, 33, 44, and 103.
The cytotoxicities of all the CTL lines against 1KLCYl were eliminated by anti-Thy-l.2 mAb and anti-Lyt-2.2 (CD8) mAb, but not anti-L3T4 (CD4) mAb and complement, and were blocked by anti-CD3E mAb (125-2Cll), anti-TCR-fl mAb (H57-597), and anti-Lyt-2.2 (CD8) mAb, but not anti-TC1k-~ mAb (3A10) or anti-L3T4 (CD4) mAb in the absence of exogenously added complement.
The direct cytotoxicities of the bulk and the six cloned CTL lines were essentially similar. All the CTL lines showed cytotoxicity against IKLO'I, but not RLcY4, RLQ8, BALB-IKVA, C, D, P815, or normal splenic Con A blasts from 
Fractionation of Acid Extract from Whole RLcrl Cells by
Reversed-phase HPLC. A sample of 2.5 x 10 ll RLcYl ascites cells from 250 BALB/c mice was homogenized with 0.1% TFA. The homogenate was centrifuged at 100,000 g for 30 rain, and materials of <5,000 daltons were obtained by filtering the supernatant on a molecular cut-offmembrane and were separated by reversed-phase HPLC on a semipreparalive C18 (ODP) column at an elution rate of 2 ml/min with an increasing concentration of acetonitrile. Each HPLC fraction (5 #1) was incubated with 51Cr-labeled P815 target and cytotoxicity by RLo'I CTL was determined. As shown in Fig. 2 A, Arrows indicate active fractions.
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Leukemia Antigen Peptide Recognized by CTL in fraction 12, and the active peptide in peak b was eluted in fraction 30. Fraction 12 derived from peak a at a neutral pH was purified by repeated HPLC (seven times) and was subjected to gel filtration. The active fraction was then separated by reversed-phase HPLC in acidic conditions on an analytical C2/C18 column in fractions of 250/~1/15 s and each fraction was tested for sensitization activity (Fig. 6 A) . Fractions with peak sensitization activity were denoted as a'. Fraction 30 from peak b in neutral pH conditions was purified by repeated HPLC (six times) and was separated by reversedphase HPLC in acidic conditions on an analytical C2/C18 column and collected in fractions of 100/xl/6 s and each fraction was similarly tested for sensitization activity (Fig. 6 B) . The fractions with peak sensitization activity were denoted as b'. SIIPGLPLSL was slightly less than that of IPGLPLSL. Anal-),sis by reversed-phase HPLC on a semipreparative C18 column revealed that the peptide IPGLPLSL was eluted in 23 min, and the peptide SIIPGLPLSL was eluted in 26 min (Fig. 7  B) . Peptides IPGLPLSL and SIIPGLPLSL were denoted as pRLla and b, respectively. Therefore, we synthesized IIIPGLPLSL and investigated its sensitization activity. Results showed that its sensitization activity was as high as that of pRLlb (SIIPGLPLSL) (data not shown).
Amino Acid Sequence
Discussion
CD8 § CTL recognize a peptide fragment in association with a MHC class I molecule (27) . The amino acid sequences of naturally occurring peptides recognized by CTL have been determined by two alternative approaches. One is determination of amino acid sequences based on information on the nucleotide sequences that are responsible for susceptibility of target cells to lysis by CTL. Boon's group identified several genes (28) identified several genes encoding tumor rejection antigens in mice and humans. Mouse mastocytoma P815 expresses several distinct antigens that are recognized by syngeneic (DBA/2) CTL. By transfecting a cosmid library derived from P815 cells into a variant that did not express P815A and P815B antigens and by packaging directly the DNA of a transfectant with )~phage extracts, they isolated gene P1A, which directs the expression of both antigens (29) . One variant that had lost only antigen A displayed a point mutation. Synthetic peptides that corresponded to the normal sequence located in the region of this point mutation sensitized target cells (30) . The PIA gene in this cell line is not mutated, but the gene is not expressed normally. They extended their analyses to human tumors and identified the MAGE gene family in a malignant melanoma. Nonapeptides encoded by MAGE-I and -3 genes are recognized in association with HLA-A1 (31) (32) (33) . Furthermore, they found that two nonapeptides encoded by the tyrosinase gene are recognized in association with HLA-A2 on tumors by autologous CTL (34, 35) .
The other approach for determination of the amino acid sequences of naturally occurring peptides recognized by CTL involves extraction of the peptides from MHC molecules, and their purification and direct sequencing. Peptides that sensitize targets to lysis by specific CTL can be extracted with acid from cells expressing appropriate class I molecules (36) (37) (38) , and attempts have been made to sequence these peptides. There are several reports on determinations of their amino acid sequences. Udaka (43) reported an octapeptide on murine Lewis lung carcinoma (3LL) recognized by specific CTL. This peptide originates from mutated connexin 37. In this study, we identified a pRL1 peptide on BALB/c radiation-induced leukemia RLcYl that is recognized by specific CTL and showed that it is derived from the akt oncogene.
An acid extract of RLo'I cells was fractionated by reversedphase HPLC on a semipreparative C18 column. Fractions eluted in 23 rain (peak a) and 26 min (peak b) showed sensitization activity on P815 cells for the bulk and all six cloned RLCel specific CTL lines. Antibody blocking indicated that recognition of the P815 target sensitized with either the peak a or b fraction by RLcYl CTL was restricted to L a like that of the RLcYl target (data not shown). Competitive inhibition assays showed that the RLo'I cytotoxicities of the bulk and cloned CTL lines were inhibited by P815 target cells sensitized with either the peak a or b fraction as efficiently as by unlabeled RLcYl. These findings suggest that the peptides in the peak a and b fractions bind to the L a molecule and create a common antigenic epitope that is dominantly recognized by anti-RLcYl CTL. Amino acid sequence anal-),sis by Edman degradation revealed an octamer peptide pRLla (IPGLPLSL) in the peak a fraction and a decamer peptide pRLlb (SIIPGLPLSL) in the peak b fraction. The sensitization activities of these peptides on P815 and the L dtransfected L cell line T1.1.1 were observed at concentrations as low as 1-100 nM with the bulk and all six cloned CTL lines tested. In a 4-h cytotoxicity assay, sensitization activity of the pRLla peptide was observed in medium with or without serum, whereas that of the pRLlb peptide was diminished in medium without serum (data not shown). These findings suggest conversion of pRLlb to pRLla by peptidases present in FCS. There are several reports of generation of optimal sized peptides from larger fragments by specific extracellular peptidases in cells sensitized with exogenous peptides to class/-restricted cytotoxic T cells. Exogenously added 11-met peptide 147-158/R-of the influenza virus nucleoprotein (form altered at residues 147-158, in which the Arg at position 156 is deleted) was presented resulting from removal of the COOH-terminal Thr and Gly by the angiotensinconverting enzyme (ACE) present in FCS (44) . Cleavage by ACE was also observed with the HIV-1 gp160-derived 15-mer peptide p18 presented by H-2D d (45) . Furthermore, recently, it has been shown that the sensitization activity of the naturally occurring 16-met peptide p2Cb (see above) appears to be due to cleavage of eight NH2-terminal residues in medium containing serum during the course of cytotoxicity assay (40) .
There is a report that in a whole cell extract of minor H antigen H-4b-positive cells, H-4-specific Kb-restricted CTL B21W9 recognized two HPLC fractions (38) . But in peptide mixtures eluted from purified K b molecules of the same cells, CTL recognize only one. In our study, using an acid extract from affinity-purified L a molecules of RLo'I, the reversed-phase HPLC fraction eluted in 23 min but not that eluted in 26 min from a semipreparative C18 column had sensitization activity. This finding suggests that the octamer peptide pRLla (IPGLPLSL) is the CTL-recognizing peptide that is presented by L a molecules on the RLO'I cell surface and that it is generated from the pRLlb (SIIPGPLPSL) peptide by removal of Ser and lie from the NHz terminus. Thus, pRLlb could be an intermediate in the processing pathway from intracellular protein to the octamer bound to class I molecules. Udaka et al. (40) showed that incubation of p2Cb with purified proteasomes resulted in a new peak of material with sensitizing activity that had the same retention time as octamer peptide p2Ca, which was concluded previously to be the active peptide recognized by 2C cells. The findings suggest that p2Cb is a precursor of p2Ca, the final product in the processing pathway. An alternative possibility is that the binding affinity of pRLlb to the L d molecule is much lower than that of pRLla and, therefore, resulted in poor recovery of the peptide on elution from affinity-purified L a molecules.
It is usually difficult to determine the sequence of a CTLrecognizing peptide directly because of limitation in the amount of peptide available. A sample of 5-10 nmol of starting material would be required for several rounds of purification for obtaining a single peak that can be assumed to contain one or two peptides (46) , although only 150-200 target peptides presented on a class I molecule seem to be required for target cell lysis when recognized by CTL (47) . In the present study, in three sequential purification procedures by HPLC, the final yield was ~5%. Since the yield from 2.5 x 1011 cells was m40 pmol, the number ofpRL1 peptides on a single RLcYl cell was calculated to be *2,000.
Oncogenes are often mutated or overexpressed in malignant cells (48) . C57BL/10 mice immunized with vaccinia virus expressing either the mutated or nonmutated ms gene were found to generate CTL specific for the peptides used for immunization (49) . BALB/c mice immunized with spleen cells pulsed with mutated p53 peptide generated specific CTL (50) . Furthermore, CTL were generated in B6 spleen cells by primary in vitro stimulation with mutated ras peptide (51) . The present finding that the akt oncogene codes for pRL1 supports the findings that the oncogene product could be the epitope of a tumor rejection antigen that can be recognized by CTL. The v-akt gene was found in a defective clone of the AKT8 virus, which was an acute transforming retrovirus isolated from a AKT T cell lymphoma, and was generated by the in frame fusion of gag and c-akt. The protein encoded by v-akt is a tripartite gag-X-c-akt fusion protein of which X is a 21-amino acid peptide derived primarily from the 5' untranslated region of the gene (26) . Acquisition of transforming properties by v-akt appeared to be due to the addition of the gag-X sequences at the NH2 terminus (52) . Myristylation and membrane association of v-Akt are likely to be critical for the oncogenic properties. C-akt mRNA is expressed in all tissues tested (26) . The pRL1 peptides shown in the present study correspond to the sequence in the 5' untranslated region of c-akt, pR.Lla is derived from residues 271-278 and ptLLlb from residues 269-278 of v-Akt. The amino acid residue Ile at position 269 in v-Akt is replaced by Set in pRLlb. Since the decamer peptide IIIPGLPLSL also showed sensitization activity, Set at the NH2 terminus of pRLlb is not responsible for sensitivity to cleavage by dipeptidase.
In addition to the RLCYl unique antigen demonstrated in this study, a number of unique antigens recognized by specific CTL have been identified in other leukemias. Whether the unique antigen peptides on these leukemias are also derived from the akt oncogene or from other genes remains to be seen.
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